390 related articles for article (PubMed ID: 26439702)
1. Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.
Sahin IH; Iacobuzio-Donahue CA; O'Reilly EM
Expert Opin Ther Targets; 2016; 20(3):341-59. PubMed ID: 26439702
[TBL] [Abstract][Full Text] [Related]
2. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
Sahin IH; Lowery MA; Stadler ZK; Salo-Mullen E; Iacobuzio-Donahue CA; Kelsen DP; O'Reilly EM
Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):893-905. PubMed ID: 26881472
[TBL] [Abstract][Full Text] [Related]
3. K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?
Nussinov R; Muratcioglu S; Tsai CJ; Jang H; Gursoy A; Keskin O
Expert Opin Ther Targets; 2016 Jul; 20(7):831-42. PubMed ID: 26873344
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.
Pishvaian MJ; Brody JR
Oncology (Williston Park); 2017 Mar; 31(3):159-66, 168. PubMed ID: 28299752
[TBL] [Abstract][Full Text] [Related]
5. Emerging antibodies for the treatment of pancreatic cancer.
Andrikou K; Peterle C; Pipitone S; Salati M; Cascinu S
Expert Opin Emerg Drugs; 2017 Mar; 22(1):39-51. PubMed ID: 28253833
[TBL] [Abstract][Full Text] [Related]
6. MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma.
Gautam SK; Kumar S; Cannon A; Hall B; Bhatia R; Nasser MW; Mahapatra S; Batra SK; Jain M
Expert Opin Ther Targets; 2017 Jul; 21(7):657-669. PubMed ID: 28460571
[TBL] [Abstract][Full Text] [Related]
7. Current Systemic Treatment and Emerging Therapeutic Strategies in Pancreatic Adenocarcinoma.
Yee NS; Kazi AA; Yee RK
Curr Clin Pharmacol; 2015; 10(4):256-66. PubMed ID: 26548903
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
Zemanek T; Melichar B; Lovecek M; Soucek P; Mohelnikova-Duchonova B
Pharmacogenomics; 2019 Jan; 20(2):113-127. PubMed ID: 30539680
[TBL] [Abstract][Full Text] [Related]
9. Toward the goal of personalized therapy in pancreatic cancer by targeting the molecular phenotype.
Yee NS
Adv Exp Med Biol; 2013; 779():91-143. PubMed ID: 23288637
[TBL] [Abstract][Full Text] [Related]
10. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
[TBL] [Abstract][Full Text] [Related]
11. Brief overview of selected approaches in targeting pancreatic adenocarcinoma.
Samore WR; Gondi CS
Expert Opin Investig Drugs; 2014 Jun; 23(6):793-807. PubMed ID: 24673265
[TBL] [Abstract][Full Text] [Related]
12. Omega-3-polyunsaturated fatty acids suppress pancreatic cancer cell growth in vitro and in vivo via downregulation of Wnt/Beta-catenin signaling.
Song KS; Jing K; Kim JS; Yun EJ; Shin S; Seo KS; Park JH; Heo JY; Kang JX; Suh KS; Wu T; Park JI; Kweon GR; Yoon WH; Hwang BD; Lim K
Pancreatology; 2011; 11(6):574-84. PubMed ID: 22213040
[TBL] [Abstract][Full Text] [Related]
13. Targeting Pancreatic Cancer Metastasis by Inhibition of Vav1, a Driver of Tumor Cell Invasion.
Razidlo GL; Magnine C; Sletten AC; Hurley RM; Almada LL; Fernandez-Zapico ME; Ji B; McNiven MA
Cancer Res; 2015 Jul; 75(14):2907-15. PubMed ID: 25977335
[TBL] [Abstract][Full Text] [Related]
14. New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies.
Matera R; Saif MW
Expert Opin Emerg Drugs; 2017 Sep; 22(3):223-233. PubMed ID: 28783977
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic Cancer and Therapy: Role and Regulation of Cancer Stem Cells.
Barman S; Fatima I; Singh AB; Dhawan P
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946266
[TBL] [Abstract][Full Text] [Related]
16. Molecular and genetic bases of pancreatic cancer.
Vaccaro V; Gelibter A; Bria E; Iapicca P; Cappello P; Di Modugno F; Pino MS; Nuzzo C; Cognetti F; Novelli F; Nistico P; Milella M
Curr Drug Targets; 2012 Jun; 13(6):731-43. PubMed ID: 22458519
[TBL] [Abstract][Full Text] [Related]
17. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.
Matsuoka T; Yashiro M
World J Gastroenterol; 2016 Jan; 22(2):776-89. PubMed ID: 26811624
[TBL] [Abstract][Full Text] [Related]
18. Lupeol, a fruit and vegetable based triterpene, induces apoptotic death of human pancreatic adenocarcinoma cells via inhibition of Ras signaling pathway.
Saleem M; Kaur S; Kweon MH; Adhami VM; Afaq F; Mukhtar H
Carcinogenesis; 2005 Nov; 26(11):1956-64. PubMed ID: 15958516
[TBL] [Abstract][Full Text] [Related]
19. Aberrant signaling pathways in pancreatic cancer: a two compartment view.
McCleary-Wheeler AL; McWilliams R; Fernandez-Zapico ME
Mol Carcinog; 2012 Jan; 51(1):25-39. PubMed ID: 22162229
[TBL] [Abstract][Full Text] [Related]
20. Mutation Profiling of Clinically Advanced Cancers Using Next-Generation Sequencing for Targeted Therapy: A Lifespan Experience.
Friedman K; Resnick MB; Safran H
R I Med J (2013); 2015 Oct; 98(10):16-20. PubMed ID: 26422540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
